Immunic’s Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis did not meet its primary endpoint of reducing brain volume loss. The study enrolled 467 patients with primary or secondary progressive MS.

Exploratory results showed that patients treated with the drug were more likely to experience confirmed disability improvement. Immunic also reported favorable trends in reducing the risk of confirmed disability worsening over 24 weeks.

Citing these signals and the drug’s favorable safety profile, Immunic plans to proceed with a Phase 3 registration trial in progressive MS. Vidofludimus calcium is also in late-stage trials for relapsing MS.